Measuring and Mapping Cognitive Decline After Brain Radiosurgery

Launched by UNIVERSITY OF NOTTINGHAM · Jun 13, 2024

Keywords

ClinConnect Summary

This clinical trial is studying how a specific type of treatment for brain tumors, called Stereotactic Radiosurgery (SRS), affects brain function over time. SRS is often used to treat patients with brain metastases (cancer that has spread to the brain) and meningiomas (a type of benign tumor). The researchers want to understand which areas of the brain may be impacted by this treatment, especially since brain function tests aren’t routinely done for these patients. By identifying these areas, they hope to adjust the treatment in the future to reduce any side effects.

To participate in this study, patients must be over 18 years old and diagnosed with either brain metastases or meningioma. They should also be able to provide informed consent and have a life expectancy of more than six months. Participants will complete brain function tests and quality-of-life questionnaires before treatment and every three months for a year, while some will only complete these assessments once. This study is important because it aims to improve the way we treat brain tumors and enhance the quality of life for patients undergoing SRS.

Gender

ALL

Eligibility criteria

• • Inclusion criteria Prospective Cohort
• Patients will be eligible for inclusion only if ALL of the following criteria apply:
• • Age: above 18 years, no upper limit
• • Diagnosis of brain metastases or meningioma, where the treatment is going to be stereotactic radiosurgery
• • Karnofsky Performance Status (KPS) ≥70
• • Established diagnosis of cancer with absent or controllable primary disease
• • Tumour volume of less than 20cc
• • Life expectancy of more than 6 months
• • Able to give informed consent
• • Exclusion criteria Prospective Cohort
• • Previous RT to the brain, including SRS
• • Previous surgery to the brain
• • Not willing or not able to give informed consent
• • Inclusion criteria Retrospective Cohort
• Patients will be eligible for inclusion only if ALL of the following criteria apply:
• • Age: above 18 years, no upper limit
• • Diagnosis of meningioma
• • Previous SRS treatment at least 1 year prior to inclusion in the study
• • Most recent MRI scan (within 1 year) shows stable appearances
• • Able to give informed consent
• • Exclusion criteria Retrospective Cohort
• • Previous RT to the brain, excluding SRS
• • Previous surgery to the brain
• • Not willing or not able to give informed consent